DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Blockade of Vascular Potassium Channels During Human Endotoxemia

Information source: Radboud University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Endotoxemia

Intervention: endotoxin (Drug); Potassium channel blockers: TEA, Quinin, Tolbutamide (Drug); L-NMMA (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Radboud University

Official(s) and/or principal investigator(s):
Peter Pickkers, MD, PhD, Principal Investigator, Affiliation: Radboud University

Summary

Background: Activation of NO-synthase and vascular potassium (K) channels may play a role in the sepsis-induced attenuated sensitivity to norepinephrine. We examined whether various K channel blockers and NO-synthase inhibition could restore norepinephrine sensitivity during experimental human endotoxemia.

Clinical Details

Official title: Blockade of Vascular Potassium Channels During Human Endotoxemia

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Hemodynamics

Markers of Inflammation

Cytokines

Markers of Renal Injury

Inducible NO synthase expression

NO-metabolites

Mediators of Vascular reactivity

Sensitivity to norepinephrine

Eligibility

Minimum age: 18 Years. Maximum age: 35 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- healthy volunteers

Exclusion Criteria:

- drug, alcohol, nicotine abuse

Locations and Contacts

Additional Information

Starting date: January 2003
Last updated: October 16, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017